Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Chemicals | Small Cap
Health Score : 8.26Epigral Ltd. demonstrates a robust financial profile, marked by exceptional profitability, strong growth, and a very stable, low-debt structure. The company is highly effective at turning revenue into profit and is expanding its sales and earnings at an impressive rate. Its ability to cover debt payments and dividends is outstanding, providing a great deal of financial security. The primary strengths are its minimal reliance on borrowing and its high returns on investment. On the other hand, there are areas of concern. The company's ability to cover its immediate, short-term bills with readily available cash is tight. Additionally, its massive investments in plants and equipment are not yet generating sales at a high rate. The future outlook is positive, driven by strong growth and profitability, but its tight short-term cash position and asset efficiency are key areas to monitor.
Health Score : 8.26Epigral Ltd. demonstrates a robust financial profile, marked by exceptional profitability, strong growth, and a very stable, low-debt structure. The company is highly effective at turning revenue into profit and is expanding its sales and earnings at an impressive rate. Its ability to cover debt payments and dividends is outstanding, providing a great deal of financial security. The primary strengths are its minimal reliance on borrowing and its high returns on investment. On the other hand, there are areas of concern. The company's ability to cover its immediate, short-term bills with readily available cash is tight. Additionally, its massive investments in plants and equipment are not yet generating sales at a high rate. The future outlook is positive, driven by strong growth and profitability, but its tight short-term cash position and asset efficiency are key areas to monitor.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
14.23
Industry Median
36.94
Small Cap Median
36.05
P/E RATIO
14.27
P/B RATIO
2.13
Industry Median
2.74
Small Cap Median
2.46
P/S RATIO
1.87
Industry Median
2.52
Small Cap Median
2.16
Others
PEG RATIO
0.53
EV/EBITDA RATIO
8.73
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1098.4 as on Aug 15, 2026.
Growth Score : 10.00The company is experiencing an exceptional growth phase, with strong expansion across all key financial metrics. It has shown a remarkable ability to increase its revenues, operating profits, and earnings per share. This top-line and bottom-line growth is supported by a steady expansion of its asset base, indicating reinvestment for future capacity. This broad-based growth is a very positive signal of high market demand and effective strategic execution, positioning the company as a strong performer in its industry.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 87.09 | 41.07 | -11.84 | 32.19 | -0.9 |
| Operating Profit Growth Rate | 95.02 | 35.36 | -30.19 | 47.82 | -20.39 |
| Earnings Per Share (EPS) Growth | 148.53 | 39.76 | -44.56 | 75.88 | -7.19 |
| Asset Growth Rate | 46.58 | 14.5 | 14.88 | 12.81 | 11.2 |
| Net Income Growth Rate | 150.5 | 39.53 | -44.48 | 82.65 | -7.26 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Alkyl Amines Chemicals Ltd | 8.65 | 48.57 | Highly Overvalued | 257.00 | 35.19 | 201.00 |
| 2 | Rossari Biotech Ltd | 8.46 | 18.67 | Neutral | 286.00 | 25.79 | 149.00 |
| 3 | Fineotex Chemical Ltd | 8.39 | 46.62 | Neutral | 135.00 | 0.79 | 125.00 |
| 4 | Epigral Ltd | 8.26 | 14.27 | Undervalued | 566.00 | 77.19 | 332.00 |
| 5 | Galaxy Surfactants Ltd | 8.17 | 33.26 | Neutral | 475.00 | 42.88 | 267.00 |
| 6 | Clean Science & Technology Ltd | 8.17 | 38.01 | Overvalued | 355.00 | 23.64 | 230.00 |
| 7 | Styrenix Performance Materials Ltd | 8.12 | 21.00 | Undervalued | 343.00 | 133.22 | 183.00 |
| 8 | Balaji Amines Ltd | 7.71 | 41.35 | Overvalued | 265.00 | 51.09 | 169.00 |
| 9 | Tatva Chintan Pharma Chem Ltd | 7.13 | 95.51 | Highly Overvalued | 93.00 | 16.71 | 42.00 |
| 10 | Neogen Chemicals Ltd | 6.69 | 202.28 | Highly Overvalued | 137.00 | 17.15 | 29.00 |
| 11 | Laxmi Organic Industries Ltd | 6.17 | 61.56 | Neutral | 171.00 | 2.86 | 79.00 |
| 12 | Camlin Fine Sciences Ltd | 5.80 | 72.06 | Neutral | 107.00 | -1.72 | 24.00 |
| 13 | NOCIL Ltd | 5.27 | 48.47 | Neutral | 101.00 | 3.84 | 56.00 |
| 14 | Chemplast Sanmar Ltd | 4.81 | -10.40 | Neutral | 198.00 | -63.46 | -280.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤6th May 26
Q4 FY26 Conference Call
BULLISH SENTIMENT
Concall Report⬤3rd Feb 26
Q3 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
Epigral Ltd (formerly Meghmani Finechem Ltd) is a leading Indian specialty chemical manufacturer. The company is a key producer of Chlor-Alkali products and their value-added derivatives, including Epichlorohydrin, CPVC Resin, and Hydrogen Peroxide. It serves diverse sectors like agrochemicals, pharmaceuticals, textiles, and construction, holding a significant market position in several product categories.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Epigral Ltd's P/E ratio (TTM) is 14.23, compared to the industry median of 36.94 and large cap median of 36.05.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Epigral Ltd's P/B ratio is 2.13, compared to the industry median of 2.74 and large cap median of 2.46.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Epigral Ltd's P/S ratio is 1.87, compared to the industry median of 2.52 and large cap median of 2.16.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Epigral Ltd's PEG ratio is 0.53.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Epigral Ltd's EV/EBITDA ratio is 8.73.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Epigral Ltd's ROE is 14.95%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Epigral Ltd's ROA is 16.15%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Epigral Ltd's ROCE is 15%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Epigral Ltd's operating margin is 22.40%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Epigral Ltd's net margin is 13.14%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Epigral Ltd's current ratio is 0.97.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Epigral Ltd's debt-to-equity ratio is 0.15.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Epigral Ltd's interest coverage ratio is 5.74.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Epigral Ltd's DPS is ₹4.62.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Epigral Ltd's EPS is -7.19.
(Source line: "Ratios as of 15 Aug 2026, based on last traded price of ₹1098.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Epigral Ltd was incorporated in 2007 as Meghmani Finechem Limited. It commenced commercial production of Caustic Chlorine in 2008. The company expanded its capacities and diversified its product portfolio over the years, successfully completing its IPO and listing on exchanges in 2021. Key milestones include commissioning plants for Epichlorohydrin, CPVC resin, and Hydrogen Peroxide between 2021-2022. In 2023, the company changed its name to Epigral Ltd, reflecting its strategic focus on specialty chemicals and derivatives.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Chlor-Alkali Products | ~50-55% | Operating Profit |
| Derivatives (ECH, CPVC, H2O2) | ~45-50% | Operating Profit |
Jayanti Patel: Chairman & Whole-time Director. A co-founder of the Meghmani Group, he brings extensive experience in the chemical industry, guiding the group's strategic vision. Maulik Patel: Managing Director & CEO. He has been instrumental in the company's growth, leading strategic initiatives, operational excellence, and product diversification.
No major subsidiaries reported.
Initial Public Offering (IPO) in 2021. Company name changed from Meghmani Finechem Ltd to Epigral Ltd in 2023.
References
The Epigral Ltd share price today is ₹1098.40 on NSE (EPIGRAL), as of 16 Aug 2026.
As of 15 Aug 2026, Epigral Ltd share price is ₹1098.40, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Epigral Ltd's market cap is ₹4,734.1 crore (Small Cap).
Epigral Ltd's current P/E ratio is 14.23, compared to the CHEMICALS & PETROCHEMICALS sector average of 34.
Epigral Ltd's current P/B ratio is 2.13.
Epigral Ltd's current dividend yield is 0.42%. Last dividend of ₹2.50 per share was declared on 16-Aug-2023.
Epigral Ltd's EPS (TTM) is ₹-7.19.
Epigral Ltd (formerly Meghmani Finechem Ltd) is a leading Indian specialty chemical manufacturer. The company is a key producer of Chlor-Alkali products and their value-added derivatives, including Epichlorohydrin, CPVC Resin, and Hydrogen Peroxide. It serves diverse sectors like agrochemicals, pharmaceuticals, textiles, and construction, holding a significant market position in several product categories.
Epigral Ltd is promoted by Meghmani Group, holding 68.83% as of 15 Aug 2026.
Epigral Ltd is listed on NSE (EPIGRAL) and BSE (543332). Its next quarterly results are expected on August 2024 (Q1 FY25).
Capital Expenditures (CapEx)
Quick Ratio